BridgeBio Pharma, Inc. — Director's Dealing 2020

Sep 23, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2020-09-18

Reporting Person: HENDERSON MICHAEL THOMAS (Chief Business Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-09-18	Common Stock	M	4901	$0.16	Acquired	272652	Direct
2020-09-18	Common Stock	M	5099	$0.28	Acquired	277751	Direct
2020-09-18	Common Stock	S	10000	$40.00	Disposed	267751	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-09-18	Stock Option (Right to Buy)	$0.16	M	4901	Disposed	2028-08-26	Common Stock (4901)	Direct
2020-09-18	Stock Option (Right to Buy)	$0.28	M	5099	Disposed	2027-11-13	Common Stock (5099)	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 18, 2020.